Recent Advancement Of Biologics In Asthma

By

Al- Shahriar Evan

18146045

A thesis submitted to the Department of Pharmacy in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (Hons.)

School of Pharmacy

Brac University

March 2022

Declaration

It is hereby declared that

1. The thesis submitted is my own original work while completing degree at Brac University.
2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
3. The thesis does not contain material that has been accepted or submitted, for any other degree or diploma at a university or other institution.
4. I have acknowledged all main sources of help.

Student's Full Name & Signature:



AL-Shahrirar Evan

18146045

Approval

The thesis titled "Recent Advancement Of Biologics In Asthma" submitted by Al-Shahriar Evan,18146045, of Summer, 2021 has been accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelor of Pharmacy (Hons.) on 30th March, 2022

Examining Committee:

Supervisor:



(Member) Dr. Sabrina Sharmin

Assistant Professor, School of Pharmacy

BRAC University

Program Coordinator:

(Member) Namara Mariam Chowdhury

Lecturer, School of Pharmacy

BRAC University

Deputy Chair : _____

Dr. Hasina Yasmin

Professor and Deputy Chair,

(Member)

School of Pharmacy

BRAC University

Dean,School Of Pharmacy :

_____

(Chair)

Dr. Eva Rahman Kabir

Professor and Dean, School of Pharmacy

BRAC University

Ethics Statement

This study does not involve any kind of animal and human trial.

Abstract

It is quite visible that in the comparison to the patients having well-controlled asthma, patients having severe uncontrolled asthma do have disproportionately high rate of morbidity and also health-care usage. Whereas the treatment choices for these individuals were largely limited and associated with significant side/adverse effects, development of the biologic medicines in order to treat asthma has presented promising/efficient targeted/focused therapy that has shown potential in the clinical setting for the patients. Patients having endotype-driven by type-2 (T2) inflammation may benefit from biologic medicines as these target distinctive inflammatory pathways implicated in the pathogenesis/etiology of asthma. Beyond anti-IGE therapy, which has been shown to improve results within allergic-asthma for over a time periode that is somewhat a decade, 3 anti-ILn-5 biologic medicines as well as 1 anti-ILn-4R biologic drug appeared currently as quite prospective therapies for Type 2 asthma. Such specific/targeted treatment/therapies have indeed been demonstrated to minimize exacerbations of asthma, enhance lung capacity/function, lower the usage of OrCS, and enhance QuOL in individuals who have been correctly chosen. In addition to those biologic medicines that have already been authorized, other biologics that target/go for upstream mediators that are related to inflammation are presently being tested in the clinical trials, and there is high chance of the approval on the way in the near future. This article will be reviewing the MeOA, possible indications, projected benefits, also adverse effects of each of the already licensed biologics as well as highlight prospective therapeutic targets that will be covered up in future. Also in the articles, alarmins and anti-alarmins therapy are discussed . It is discussed in this article what the impacts of alarmins are and what the prospective function of anti-alarmins may be in the context/perspective of already available biologics.

Keywords: Asthma, Biologics, Monoclonal-antibodies, Lung capacity/function,Interleukins

Acknowledgment

First of all, my highest gratitude is for Almighty Allah SWT for giving me the opportunity, strength and patience to complete my project work properly. I am thankful to Dr.Sabrina Sharmin miss (Assistant Professor, School of Pharmacy, BRAC University), my respected project supervisor for her kind guidance regarding my work. Moreover, my special thanks to Dr. Eva Rahman Kabir, (Dean and Professor, School of Pharmacy, BRAC University) for giving me the opportunity to conduct my project work successfully. Lastly, my sincere gratitude is towards my parents, family and friends for their motivation and support throughout the journey.

Table of Contents

List of Figures

List of Tables

Abbreviations

FEV1 = Forced Expiratory Volume in One Second

IGE = Immunoglobulin E

RCTls = Randomized Control Trials

InCS = Inhaled Cortico Steroids

OrCS = Oral Cortico Steroids

HeNO = Highly Exhaled NO

FreNO = Fractional Exhaled NO

QuOL =Quality of life

Interleukin = ILn

ThARC = Thymus and activation regulated chemokine

LoABA= Long Acting β agonist

ThSlP = Thymic Stromal lymphopoietin

AEC = Association of Absolute Eosinophil count

MeOA = Mechanism of Action

SGRO = St. Georges Respiratory Questionnaire

QOLQ = Quality of Life Questionnaire

BBW = Black Box Warning

NK cells =Natural Killer Cells

ADCMC = Antibody Directed Cell Mediated cytotoxicity

AiHR= Airway-Hyperresponsiveness

LAR= Late Asthmatic Response

Chapter 1

1.1 Introduction

With more than 300 million individuals suffering with asthma throughout the world, it is the most common chronic inflammatory illness of the airways . It is characterized by bronchial hyperresponsiveness and fluctuating airflow restriction . While the vast majority of asthma patients can accomplish disease control with standard controller therapy , nearly 5% of patients have severe asthma that remains uncontrollable even after complying to conventional treatments with an elevated inhaled corticosteroid (ICS) and furthermore a long-acting bronchodilator (LABA). If severe asthma is present, patients are more likely to require hospitalization, to experience negative side effects with oral corticosteroids (OrCS), to have poor quality of life (QuOL), and to have an impeded lifestyle as compared to individuals with well-controlled illness.Biologics can play a role here as they have the ability to act like a targeted therapy or medicine .

1.2 Rationale Of The Study

It is possible to create biologic medications from the cells of live organisms like bacteria or mice, which are then genetically engineered to target particular molecules inside humans. Antibodies, inflammatory components, and cell-receptors are indeed the primary targets for asthma treatment. Biologics operate by targeting specific molecules in the body to interrupt the mechanisms that create inflammation, which in turn triggers asthma symptoms. Individuals who continue to experience symptoms while using routine daily controller drugs are candidates for biologic therapy. Biosimilars have shown the most significant reduction in the incidence of asthma

exacerbations, which include routes to the emergency department, hospitalizations, and the requirement for OrCS. Additional advantages include decreased asthma symptoms, a decrease in the dose of some of the other asthma controller medications, and a decrease in the number of absent school and working days. It has been demonstrated that biologics can enhance the quality-of-life for individuals with asthma. In individuals with severe asthma, it has been discovered that several biologics can enhance lung capacity/function.

1.3 Aim Of The Project

The most prevalent chronic-inflammatory respiratory/airway disease, asthma affects approximately 300 million people across the globe and is the most frequent chronic respiratory condition. Identification and avoidance of triggers, daily inhalation or oral controller medicine, as well as the use of an emergency rapid-relief inhaler when symptoms start, are all effective methods of controlling asthma for many individuals with the condition. However, for some people, these drugs are insufficient to keep their asthma under control. In recent times, a number of novel drugs, commonly referred to as "biologics," have indeed been licensed for the mission of the treatment of moderate-to-severe asthma. Biologics are distinct in that way that theese are designed to target a particular antibody, or even a molecule, or sometimes a cell that are thought to be involved of the development of asthma. They are referred to as "precision" as well as "tailored" therapy as a result of this distinction. The goal of this study is to determine the effectiveness of biologics in the treatment of asthma that are already in use and also those that are under ongoing researches.

Chapter 2

Methodology

Initially, 70 papers were collected based on my topic from a various internet sources which include PubMed, Research Gate, Elsevier and Science direct by thorough research. From all of those papers,60 were chosen based on relevancy and finally 48 papers which had most recent years of publications were selected with the intention of getting the most updated information. After that, all the information were mixed and matched and re-organized and an outline was created followed by a comprehensive review of all these papers. Lastly, all the selected information were re-written and references were added with the help of Mendeley library to specify the sources of those information. Thus, this review on 'Recent Advancement Of Biologics In Asthma' was carried out .

Chapter 3

An overview On Asthma

3.1 What is Asthma

Asthma is a chronic lung illness characterized by reversible airflow restriction, hyperresponsiveness of the airways, and inflammation of the airways. Asthma is a chronic lung condition defined by reversible airway restriction, airway hyperresponsiveness, and inflammatory processes. Shortness of breath, cough, wheezing, and tightness of the chest are common symptoms. While no widely accepted definition of an asthma exacerbation exists, clinical trials usually define a serious exacerbation as involving systemic corticosteroids, hospitalization, or emergency medical care for rapidly deteriorating asthma, or a reduction in morning maximum discharge of more than 25% from baseline on two days. (Dougherty & Fahy, 2009)

Asthma attacks the lungs, which are the main organ that suffers the most damage. The lungs are organized into lobes and segment, with the right lung having ten segments and the left lung having eight or nine, based on the lobe division. The connecting zone and the respiratory zone are anatomically separated in the respiratory system. The respiratory zone travels from of the alveolar duct to the alveoli, wherein gas exchange occurs, while the conducting zone runs from the nose to the bronchioles. The bronchial tree, which distributes air all through the lungs till it enters the alveolar sacs, is affected by asthma. (Sinyor & Perez, 2021)

The bronchi start at the end of the trachea and split into left and right bronchi. The right bronchus has a bigger diameter and is positioned more vertically, while the left bronchus is small and orientated more horizontally. The bronchi are then classified as secondary or tertiary bronchi.

Smooth muscle and elastic fibers keep the bronchial walls intact, which change as inflammatory mediators, bronchoconstrictors, and bronchodilators constrict and relax smooth muscle. As one moves from of the bronchi to the alveoli, the number of smooth muscle fibers increases. In normal respiratory physiology, lung compliance refers to the ability of the lungs to expand, while elastance defined as the ability of the lungs to revert to their resting position. As a consequence of inflammation, the physiological mechanism in asthma patients changes, reducing the diameter of the airway. By altering the responsiveness of the lungs, each of these organs work together just to increase slightly the labor of breathing. (Sinyor & Perez, 2021)

During the next several hours, the eosinophils ,the basophils, the neutrophils, the helper and also the memory T cells migrate towards lungs, causing bronchoconstriction as well as inflammation. Mast cells also play a role in transporting late-phase substances to inflamed regions. Understanding both of these processes is crucial depending on the severity of the problem in order to target therapy and reduce the bronchoconstriction and inflammation. Individuals with a thicker airway have a longer sickness duration over time due to a smaller airway. As a consequence of inflammation and bronchoconstriction, there is an occasional airflow blockage, resulting in increased labored breathing. (Sinyor & Perez, 2021)

.

Asthma is characterized by airway hyperresponsiveness, or perhaps an enhanced bronchoconstrictor response to numerous stimuli. A variety of factors can produce airway hyperresponsiveness. Two probable causes are higher histamine from mast cells or enhanced airway smooth muscle hypertrophy. There's also a rise in vagal activity and levels of free calcium,

which helps airway smooth muscle cells contract better. The extent of Airway-hyperresponsiveness is determined through bronchial provocation testing. (Sinyor & Perez, 2021)

As Airway-hyperresponsiveness is connected to a slower loss of lung function and a higher likelihood of acquiring and aggravating asthma from child to adult, this trait is clinically important. As a result, asthma and hyperresponsiveness can be treated with early intervention. By altering the flexibility of the lungs, every one of these systems works together to increase slightly the labor of breathing. As inflammation, granular white blood cells, exudate, and mucus clog the bronchiolar trees, it can become increasingly difficult for a person to breathe properly. The epithelium thickens as the quantity of myofibroblasts, which make collagen, increases, restricting the smooth muscle layers and lamina reticular. As a consequence, the basement membrane has greatly thickened. In some persons, airway remodeling is hypothesized to create a permanent restriction of airflow.(Sinyor & Perez, 2021)

Remodeling occurs when epithelial cells become mesenchymal cells, increasing the smooth muscle content. Epithelial cells loses their adhesion and physiological polarity as a result of tight connections, transforming them into mesenchymal cells. In response to mast cell interactions, eosinophils can aggravate airway remodeling by producing Transforming Growth Factor Beta (TGF-B) and cytokines. These processes of airway remodeling, if not treated and managed effectively, can worsen inflammation and aggravate asthma throughout time. Expiratory airflow limitation, proof of reversible blockage, and the absence of any other diagnosis are all factors that must be determined by tests. (Sinyor & Perez, 2021)

To rule out asthma, spirometry is utilized to examine the person's obstruction, and a transient change after a bronchodilator is checked. Spirometry can be used to detect asthma and indicate the extent of obstruction. An blockage of air is defined as spirometry with a Forced expiratory volume in one second (FEV1) or less 0.8 and a Forced expiratory volume in one second by Forced vital capacity ratio (FEV1/FVC) less than 0.70. This ratio is known as the Tiffeneau-Pinelli index. The FEV1 and FEV1/FVC ratio values are lower, the worse the asthma is. Spirometry and bronchoprovocation testing with methacholine are also typical methods of testing. Methacholine is a muscarinic agonist which acts on M1, M2, and M3 receptors in the lungs to constrict smooth muscle. Methacholine can be used to determine the degree of bronchoconstriction. Allergy testing isn't usually helpful in identifying asthma, but this can assist identify the triggers that aggravate the cond. (Sinyor & Perez, 2021)

3.2 Cell Biology of Asthma

3.2.1 Pathophysiology and Pathogenesis of Asthma

3.2.1.1 Bronchoconstriction

Asthma is pretty well-known for being a prevalent respiratory disorder which is kind of chronic defined as an increased inclining/tendency towards airway-constriction which is reversible in the clinical setting. This can occur as a result of daily environmental exposure and is exacerbated by intercurrent infection as well as allergen exposure in sensitive individuals. Asthma is characterized by airway inflammatory conditions and structural modifications within tissues of the airway, like hyperplasia of the epithelial-globlet-cell, subepithelial-collagen deposition, as well as hypertrophy of smooth-muscle , generally recognized as the airway remodeling.

Bronchoconstriction is characterized by high mechanical stresses inside the airways, that compel tissue-cells to be twisted and contracted, and mechanical stresses in other organs are known to cause tissue remodeling. Ex-vivo pressure applied to the epithelium epithelium results in modifications that are consistent with those seen and associated with the remodeling/restructuring in-vivo, according to in vitro investigations in a number of models. As a result, we hypothesized that perhaps the airway constriction produced by the exposure to the allergen in-vivo in asthma patients might have been a substantial stimulation for enabling the airway-remodeling to develop. In order to examine this idea, participants with mild atopic asthma were given repeated challenges at the presence of either an allergen (to cause bronchoconstriction and eosinophil recruitment inside thie airway) or the methacholine (in order to generate the bronchoconstriction specifically). Additionally, 2 additional groups of the asthmatic volunteers participated as the control-groups, undergoing numerous tests/challenges either with the saline placebo (in order to regulate the procedures) or the methacholine following taking albuterol to prevent bronchoconstriction . Ultimately, The end product is the impact of such challenges on the airway and was investigated using changes in markers of the airway-remodeling within the endobronchial tissue gathered using the fiberoptic bronchoscopy at the time of the challenge.(Bullone et al., 2019)

3.2.1.2 Airway edema

Asthmatics have a T-helper cell (Th)-2 profile inflammation in their airways, which includes an excess of eosinophils, mast cells, and Th-2 lymphocytes. These inflammatory cells produce mediators that cause bronchospasm, mucus secretion, and perhaps remodelling. In patients treated with InCS, the amount of infiltrating leukocytes such as mast cells, eosinophils, CD8+ and CD45+

T cells correlates with AiHR . Th-2 cytokines interleukin (ILn)-4, ILn-5, ILn-9, and ILn-13, transforming growth factor (TGF)-beta, granulocyte/macrophage colony-stimulating factor (GM-CSF), lipid mediators, and histamine are among the inflammatory mediators that promote this phase. TGF-beta, ILn-15, and ILn-17 are examples of these mediators.(Elias et al., 1999)

3.2.1.3 Airway Hyperresponsiveness

Airway hyperresponsiveness (AHR) is a condition in which a patient's airways shrink abnormally in response to stimuli that have little or no effect in healthy people (Figure 1). The unusual reactions of asthmatics to non-specific stimuli first were characterized by Tiffeneau and Beauvallet in 1945 and eventually developed in both Europe and the United States during the 1960s. Cockcroft are primarily credited with popularizing the non-specific test of AiHR almost 40 years ago . AiHR has long been thought to be a key component of asthma, and measuring it has revealed a lot about the disease's underlying pathophysiology. Our understanding of AiHR has evolved significantly, and recent findings necessitate a re-evaluation of present knowledge, particularly in terms of the underlying processes. While we did not undertake a systematic review of all literature on AiHR mechanisms in asthma, we tried our best to offer a comprehensive review on the most current discoveries. We'll start with a few notable clinical studies to lay the groundwork for a discussion of how future research into the causes of AiHR could have a big impact on clinical practice. But first, let's look at a couple of case examples. Both authors have responded positively to bronchial

challenges in the past. Despite being negative to mannitol challenge, one (DC) developed AiHR to methacholine. He is now in "AHR remission" after treatment. The other (CI) has previously responded positively to exercise, methacholine, and histamine when breathed, but not when given systemically. He is currently unresponsive to methacholine, even at high doses. Even with such a small sample, a few crucial ideas emerge. To begin with, AiHR is a changing goal in that its intensity and existence are dependent on a variety of circumstances, including the agonist method used and the treatment dosage. Second, AiHR is most likely caused by a variety of underlying mechanisms, each of which will play a different role in different patients. This diversity isn't often adequately recognized. Whereas the clinical relevance of AiHR has indeed been widely discussed elsewhere (5–7), we feel that understanding the variability of the mechanisms that underpin AiHR is an often overlooked but crucial component of the jigsaw. As a result, researchers propose that future studies into the mechanism of AiHR should strive to shift away from a "one size fits all" approach to assigning specific AiHR causes to different patient populations. We believe that in this way, it will provide much-needed insight into the ever-evolving recognition of various asthma clinical characteristics.(Chapman & Irvin, 2015)

The assessment of the Airway-hyperresponsiveness is utilized mostly in diagnosis, severity categorization, and therapy of asthma. Individuals that report symptoms, specifically those who have normal/usual baseline lung function/capacity as evaluated by spirometry, may benefit from AHR. AiHR is linked to a greater loss in the overall lung function, even in individuals who are asymptomatic, a greater chance of developing asthma, and a greater likelihood of wheezing persisting into adulthood. Additionally, the intensity of AiHR is also associated with a higher risk for exacerbation, greater asthma severity which has been evaluated by the symptoms, and also an

increased degree of treatment necessary to manage symptoms. Understanding the factors that contribute to the existence and intensity of AiHR is indeed critical in enhancing asthma control as well as slowing the overall disease progression. (Chapman & Irvin, 2015)

Despite the fact that AiHR is widely thought to be a marker of asthma, it is vital to recognize that the severity/intensity and even presence of the AHR, is really not fixed. After an allergen exposure challenge , some individuals AiHR towards non-specific triggers, including histamine as well as methacholine, is elevated, but not among all of them. This rise in AiHR typically happens in people who have a delayed asthmatic response, and its permanence might be short-lived or last till several months after exposure. Furthermore, anti-inflammatory treatment/therapy has been shown to significantly improve AHR, and since its widespread/large-scaled implementation, numerous patients on adequate treatment regimens have failed of responding positively to bronchial challenges linked with asthma. For instance, in a cohort of poorly managed, persistently undertreated-asthmatics, Reddel et al presented a report that showed that Sixteen weeks of higher dose of InCS followed by dose titration resulted in a 4.0 double dose rise in PD20FEV1 (decrease in AHR). By 72 weeks, 40 percent of the individuals exhibited response to the methacholine challenge that were within the usual range. Moreover, the detection of AiHR is complicated by its low repeatability, including predictions of in-subject repeatability varying between 1–3 of doubling doses. The variation of AiHR is even higher in people with non-atopic illness and in individuals that are more than the age of 50. Despite the fact that a negative bronchial-challenge doesn't really rule out the possibility of asthma, the interpretation/assessment of a negative bronchial-challenge should be taken into account for the case of the existence or lack of presenting symptoms. A negative-challenge within an individual

having current symptoms may indicate that a diagnosis apart from asthma should be pursued. Nevertheless, a negative-challenge during a period when there are no symptoms doesn't really rule out asthma, and in light of the patient's history, it is far more acceptable to refer to this kind of a patient as "currently-negative AiHR.". (Chapman & Irvin, 2015)

3.2.1.4 Airway Remodeling

Airway remodelling points/refers to the structural alterations within both the large and the small airway that are linked to a variety of disorders, including asthma. Subepithelial fibrosis, enhanced mass of the smooth muscle,enlargement of the gland, neovascularization, and also the epithelial modifications are all associated with asthmatic airway structural changes/alterations . Airway remodelling is frequently linked to already existing chronic-inflammatory-process, despite the fact that this is debatable. These remodeling processes cause airway walls to be thickened , resulting in airway constriction, bronchial hyperresponsiveness and also the airway edema, and mucus hypersecretion. When it comes to patients having asthma, airway remodelling is linked to poor clinical results. Early detection and stoppage of airway remodelling may reduce disease intensity, enhance control, as well as minimize disease manifestation/expression . Connection among structural modifications and also the clinical-abnormalities/problems is certainly worth exploring further. (Elias et al., 1999)

3.3 Pathogenesis

Smooth muscle contraction in the walls of large and medium-sized conduction airways in the lungs causes excessive airway constriction, which can induce severe shortness of breath, respiratory failure, and death in asthmatics. Although smooth muscle is found circumferentially throughout the airways in more peripheral airways, these bands of muscle are present in the posterior portion of the human airways and bind to the anterior airway cartilage rings. Smooth muscle contraction induces airway constriction in both sites, with the most widespread constriction in medium-sized airways, which can be physiologically triggered by efferent parasympathetic neurons releasing acetylcholine or mast cells and basophils releasing histamine and cysteinyl leukotrienes. In healthy animals, like humans, physiological responses to the release of acetylcholine from efferent neurons or histamine and leukotrienes from mast cells and basophils cause very little and asymptomatic airway restriction. When large amounts of these contractile agonists are delivered straight into the airways by pharmacologic techniques, normal mammals are also resistant to considerable airway constriction. Smooth muscle contraction induces airway constriction in both sites, with the most widespread narrowing in medium-sized airways, which can be physiologically triggered by efferent parasympathetic neurons releasing acetylcholine or mast cells and basophils releasing histamine and cysteinyl leukotrienes. In healthy animals, especially humans, physiological responses to the release of acetylcholine from efferent neurons or histamine and leukotrienes from mast cells and basophils cause very little and asymptomatic airway constriction. When large amounts of these contractile agonists are delivered directly into the airways by pharmacologic techniques, normal mammals are also resistant to considerable airway constriction. People with asthma, on the other hand, have dramatically enhanced sensitivity to all of these agonists, as seen by considerable increases in airway resistance and associated decreases in maximal expiratory airflow rates during forced expiratory maneuvers. While all allergic humans discharge roughly the

same amount of bronchoconstrictors (i.e., histamine and leukotrienes) into the airways, only asthmatics encounter excessive airway shrinking in reaction to these mediators, according to latest evaluations between allergic asthmatic subjects' reactions to inhaled allergens and other subjects with likewise serious cutaneous immune responses to allergens. (*Cell Biology of Disease: The Cell Biology of Asthma*, n.d.)

The major clinical signs of asthma include constant attacks of breathlessness and wheezing that are at least partly reversible, a persistent cough, and increased airway mucus secretion. Because it necessitates an integrated response in the conducting airways of the lung to unidentified causes, asthma is a multicellular sickness involving abnormal responses of many different cell types in the lung. Airway epithelial cells are stimulated to secrete the cytokines, ThSLP, ILn-25, and ILn-33, which perform on sub epithelial dendritic cells, mast cells, and innate lymphoid cells (principally ILn-5 and ILn-13) in response to inhaled stimuli (e.g., proteases and other constituents of inhaled allergens, respiratory viruses. Environmental stimuli also stimulate afferent neurons in the airway epithelium, which can produce physiologically active chemicals. (*Cell Biology of Disease: The Cell Biology of Asthma*, n.d.)

3.3.1 Host Factors Innate Immunity

Cytokines are hormone messengers that have a role in cell-mediated immunity and allergic reactions. There are two types of pro-inflammatory (inflammation-promoting) foods: pro-inflammatory and anti-inflammatory foods (reduce inflammation). T lymphocytes, which are a key producer of cytokines and contain antigen specific receptors on their cellular surface that

enable them to detect normal tissue during autoimmune disease episodes, are next. There are two kinds of T-Lymphocytes are cluster of differentiation 4 (CD4) and cluster of differentiation 8(CD8). Helper T cells are T lymphocytes that express the cluster of differentiation 4 (CD4) protein. They are the most prolific cytokine makers in the planet. Th1 type cytokines and Th2 type cytokines are subcategories of this category of cytokines.(Zhang & An, 2007)

TH1 Cytokine

Th1 cells create pro-inflammatory reactions that destroy intracellular parasites while also disrupting autoimmune defences. The major Th1 cytokine is interferon gamma. It's vital to note that uncontrolled tissue damage might result from excessive pro-inflammatory reactions. Mechanisms for treating this form of inflammation are being researched by scientists. (Zhang & An, 2007)

TH2 Cytokine

ILn- 4, 5, 13, which are involved with the increase of IGE and eosinophilic responses in atrophy, and ILn-10 which has a greater anti-inflammatory response, make up Th-2 inflammation. Th-2 will inhibit Th1-mediated reactions when there is an oversupply of it. For immunological difficulties, experts believe that an ideal mix of Th1 and Th2 generation is preferable.(Zhang & An, 2007)

Interleukins

Consistent relationships between tissue ILn-13 levels and genetic variations in the ILn-13 gene with asthma and associated features suggest the role of ILn-13 in allergic diseases in humans. With

the overwhelming evidence pointing to ILn-13's essential involvement in allergic illnesses, researchers are focusing their efforts on deciphering the mechanisms by which this cytokine may influence the pathophysiological characteristics of allergic disease. ILn-13, rather than classic effector pathways involving eosinophil's and immunoglobulin E-mediated events, appears to generate elements of the allergic response through a broad variety of activities on resident airway cells, according to the developing paradigm. In light of these recent advances, this review examines our current knowledge of ILn-13's unique function in asthma pathogenesis, with a particular focus on new insights into the mechanisms by which ILn-13 mediates diverse asthma symptoms. (Zhang & An, 2007)

3.3.2 Genetics

Long ago, it was discovered that asthma is influenced by genetics. In several studies, it has been demonstrated that children of the asthmatic parents are already at enhanced risk of experiencing asthma, with maternal asthma being associated with a higher risk than that of the paternal asthma. Identical twins who have discordant asthma symptoms demonstrate that genes do not fully explain asthma. Multiple genetic investigations have revealed that asthma is characterized by extensive genetic heterogeneity, that is impacted by hundreds of different genes. Several genome-wide association studies, which seek for genetic variations across groups of individuals both with and without the asthmatic condition across the human genome, have found that the 17q21 region is by far the most consistently associated with asthma. In this region, mutations in four genes (IKZF3,GSDMB,ORMDL3,ZPBP2) cause folding of the proteins in the endoplasmic reticulum to become less efficient, leading to a proinflammatory response. Researchers still don't know

fully why certain people are genetically predisposed to asthma and this issue is yet to be explained further. (Mims, 2015)

3.4 Symptoms

Early warning symptoms represent changes that take place just before or also at the beginning of an asthma attack. These symptoms may emerge before more familiar asthma symptoms and also are the first signs that the asthma is becoming worse. However, by recognizing these warning signs, one can either halt or stop the asthma-attack from progressing in its progression. Early warning signs/indicators coughing, especially at night, wheezing, and having difficulty catching the breath or having shortness of breath, when one exercises, one may feel extremely exhausted or weak. After exercising, wheezing or coughing can occur. (*Asthma Attack Symptoms and Early Signs of Asthma*, n.d.)

Chronic bronchial-tube inflammation, as well as an increase at the production of viscous secretions inside the tubes, are characteristic of asthmatic symptoms. Asthma sufferers have symptoms when their airways become constrictive, inflamed, or clogged with mucus. (*Asthma Attack Symptoms and Early Signs of Asthma*, n.d.)

It is not true that everyone who has asthma suffers from the very similar symptoms in the similar way. It is possible that one will not experience each of these signs/symptoms at the similar time, or that one will experience them in different ways. One individual may notice that the asthma symptoms vary from one asthma attack to another, with one being mild and then the next being intense. (*Asthma Attack Symptoms and Early Signs of Asthma*, n.d.)

It is possible for people who have asthma to get into extended duration of time without encountering any symptoms, rather than have their lifestyles disrupted from asthma attacks, that are periodic deterioration of their symptoms. On a regular basis, some people may be troubled with asthma-like symptoms. Moreover, certain individuals may only experience asthma symptoms while they are exercising or when they are suffering from viral infections such as colds or the flue. Minor asthma attacks outnumber severe asthma attacks in terms of frequency. The severity of severe episodes is uncommon; nonetheless, they last longer and need prompt medical intervention.. Even mild/moderate asthma symptoms should be noticed and treated as soon as possible to help one to prevent severe/major attacks and also to keep asthma within control longer. (*Asthma Attack Symptoms and Early Signs of Asthma*, n.d.)

It is believed that an asthma episode is characterised from the tightening of muscular bands around the airways. This tightness is referred as as bronchospasm in medical terminology.. An attack causes the lining which situate within the airways to be become swelled or inflamed, resulting in the production of more and aslo thicker mucus than is normally produced by the cells that form the lining of the airways. Breathing problems, wheezing, coughing, breathlessness, and difficulty doing regular daily tasks are all signs of bronchospasm, inflammation, as well as production of mucus , all of which are associated with asthma and other allergies.(*Asthma Attack Symptoms and Early Signs of Asthma*, n.d.)

Aside from severe wheezing during breathing in / out, further symptoms/indications of an asthma-attack include coughing which won't stop, and chest tightness ,pain and discomfort. This also include br reathing that is really quick,pain and pressure in the chest, etractions (which are

tightened neck and also chest muscles). (*Asthma Attack Symptoms and Early Signs of Asthma,* n.d.) Given how rapidly an asthma attack may develop or the intensity of this , it's vital to treat the signs and symptoms of asthma as fast as possible. If someone does not obtain immediate treatment, for example an asthma inhaler , their breathing will become increasingly difficult .(*Asthma Attack Symptoms and Early Signs of Asthma,* n.d.)

When lungs get even more constricted, one imdividual will be unable to use the peak flow meter. His lungs will progressively tighten towards the point in which there is inadequate air circulation to induce wheezing . In other cases, individuals wrongly believe that the lack of wheezing is indeed a sign of healing and hence refuse to seek prompt medical assistance. If one does not obtain sufficient asthma treatment, that individual may become unable to speak and develop a bluish tint around lips. A reduction in the quantity of oxygen at the blood is indicated by a color shift called cyanosis. If one does not seek treatment for asthma emergency as soon as possible, he may fall unconscious and eventually die .(*Asthma Attack Symptoms and Early Signs of Asthma,* n.d.)

When it comes about children in the U.s., asthma affects 10 percent to 12 percent of them, rendering it one of the the most frequent chronic conditions among them. The frequency of asthma among children is steadily growing, and the reasons for this are unclear. Asthma symptoms can emerge at any age, but the major proportion of children experience the first symptoms during the age of 5 years old. (*Asthma Attack Symptoms and Early Signs of Asthma,* n.d.)

3.5 Environmental Factors

Environmental factors/components that cause asthma include those that generate airway-inflammation with eosinophils (which is more prevalent) or neutrophils , as well as airway-hyperresponsiveness (AiHR). The most prevalent of them (and, in fact, the most prominent cause of the asthma) are inhalant allergen exposures which are IGE-mediated. Allergen-induced AiHR and also inflammation are both related to LAR. Despite the fact that allergens were previously identified only as causes/reasons of the symptoms and also bronchoconstriction in asthmatics, it is now acknowledged them as causes of the core pathophysiologic features/aspects of asthma. Chemical sensitizers(that are of low-molecular-weight) , which are the source of the occupational-asthma, also induce asthma in such a manner that is similar to that of allergens. Acute irritant-induced-asthma after a very heavy irritants exposure as well as chronic irritant-induced-asthma resulting from repeated/multiple high exposures can both cause persistent or permanent alterations (inflammation and AiHR) associated with asthma. Textile dust exposure results in a separate type of airway illness (byssinosis), which is less commonly noticed at the present time. Children who are exposed to tobacco smoke in their environment are more likely to acquire asthma. Personal smoking and ambien/environmental air pollution have an unpredictable and most likely modest influence on the development of asthma. (Cockcroft, 2018)

3.5.1 Allergens

Asthma symptoms are significantly exacerbated by allergen exposure, which can also result in higher morbidity. Mold, dust-mite, cats, dogs, rodent, cockroach, and a variety of other indoor allergens are present in homes and also in schools across the United States. One of the most prevalent allergens associated in asthma development and also the exacerbation is the dust-

mite(Der p 1 as well as Der f 1). Dust-mite sensitization has indeed been related to asthma exacerbation. Dust-mites are microorganisms that may be found in abundance in both personal dwellings and commercial structures. These organisms thrive in moist settings. Among the most prevalent indoor hairy pets , dogs (Can f1) and the cats (Fel d 1) are mostly quite common/usual ones . Exposure/Contact to cats and dogs allergens in sensitive individuals might result in severe asthma morbidity. Children with chronic asthma are sensitive to these allergens in a proportion ranging from 25–65 percent. These allergens can be located within saliva, skin, and also follicles of hairs of cats and dogs. Pet allergens are transported throughout the air on microscopic particles, which allows these to stay airborne and stick to surfaces and clothes. Cockroaches(Bla g 1) and mouse(Mus m 1) allergens have indeed been found in high concentrations in several inner-city asthma investigations, and sensitization to and exposure/contact to such allergens have been demonstrated to be related with asthma morbidity . It can be detected within urine of mouse , dander of mouse, and hair of the mouse , as well as in the urine of other rodents. There is also evidence that the cockroaches allergen is a significant cause of indoor air allergen. Cockroach allergen can cause IGE sensitization and the onset of rhinitis or even asthma. It has been discovered that there are no immunodominant allergens present in cockroaches, which is in contrast to allergies to cats and mites. In the United States, the German cockroaches(*Blatella germanica*) and also the American cockroaches(*Periplaneta americana*) are the dominant cockroach species that cause allergy. Cockroaches allergens Bla 2 and Bla 5 are among the most commonly encountered in the United States, causing sensitization in 42–70 percent and 35–68 percent, respectively. (Stern et al., 2020)

3.5.2 Respiratory Infections

Respiratory tract infections produced by viruses and/or uncommon bacteria are known to play a role in the development and progression of asthma. Several viruses, including the respiratory-syncytial virus, rhinovirus, and also the influenza/parainfluenza viruses, have been shown to promote the development of the asthmatic phenotype, and they have also been linked in the production of exacerbations in some cases. Chlamydiae and also Mycoplasms infections, as well as airway bacterial-colonizations as well as infections, can all play a key role in this regard . As a result of their interactions with complicated immunological pathways, all of these microbial pathogens are likely to contribute to the development and exacerbation of asthma in genetically susceptible people. (Whyand et al., 2018)Click or tap here to enter text.

3.6 Types of Asthma

T2-High Asthma/ Type-2 High-Airway Inflammation

T2 inflammation is commonly seen among around half of all asthma sufferers , and this may be somewhat more prevalent in severe asthmatics. Asthma patients with T2-high condition have interactions with inhaled allergens, microorganisms, and pollutants, which results in the stimulation/activation of mediators such like ThSLP, ILn-25, and ILn-33. This process results in the activation of ILn-4, ILn-5, and ILn-13, that can lead towards the both attraction as well as activating of the basophils, the eosinophils, as well as mast-cells. This process also ends up in the secretion/flow of the IGE by the B-cells, as well as the activation of the innate cells such or instance, airway epithelium and smooth muscle. Both the allergic and the nonallergic eosinophilic asthma are classified as T2 high. T2-cytokines have a dominating role in the process

of inflammation in nonallergic eosinophilic asthma, whereas in the allergic asthma , an allergen-specific, IGE-dependent mechanism is prominent . Sputum and AEC, serum IGE level , exhaled-NO, and also the serum periostin are almost all the key indicators of T-2 inflammation which can be used to predict responsiveness to biologics.(McGregor et al., 2019)

T2-Low Asthma/ Type-2 Low-Airway Inflammation

Neutrophilic-asthma, mixed-asthma, and the paucigranulocytic-asthma are all types of T2-low asthma that have a very poorly known pathophysiology which may be impacted through the usage of corticosteroids in conjunction with other treatments to lower eosinophilia. It has been seen that T2-low-asthma is induced via the neutrophilic inflammation or the paucigranulocytic inflammation, which activates both T-1 and T-17 cells, and individuals having moderate-to-severe asthma show high ILn-17A mRNA levels/amounts. These individuals are typically lesser responsive towards the corticosteroids, have less allergy symptoms/signs , also are frequently older somewhere during the timeframe of the process of the diagnosis than the general population is. (McGregor et al., 2019)

Forms of Asthma

Allergic asthma

Asthma that is caused by allergens is the most common kind, involving more than 60% of asthma patients in the USA. The majority of people who suffer from allergic asthma also have other conditions such as eczema,also allergic rhinitis, or an allergic reaction to foods. In some cases,

particular allergens within the environment might cause allergic asthma attacks to flare up. (*Types of Asthma: Classification and Severity*, n.d.)

Nonallergic asthma

Nonallergic asthma, also known as intrinsic asthma, doesn't really require the presence of an allergen to cause an episode. It is less prevalent than that of the allergic asthma, accounting for approximately 10–33% of all instances of asthma, and is less severe. It is far more likely to manifest itself in maturity and affects females at a higher rate than males. According to experts, nonallergic asthma develops as a result of a combination of hereditary and environmental variables. (*Types of Asthma: Classification and Severity,* n.d.)

Seasonal asthma

Seasonal asthma is characterized by symptoms that appear only under specific situations or at specific seasons of the year. Throughout hay fever season, for instance, an individual having seasonal asthma may observe that symptoms are much worse or only show up during cold or hot weather conditions , thunderstorms, and unexpected temperature changes. (*Types of Asthma: Classification and Severity,* n.d.).

Occupational asthma

People who suffer from occupational asthma may notice that their symptoms get worsen during work, or even that their symptoms get improved after taking time off. In reality, occupational exposure/contact to the chemicals of paints , aerosols, insecticides, and other potentially dangerous compounds may account for as much as 15% of all asthma cases in the United States. Depending on the degree of exposure/contact to these and other chemicals, it is possible that the onset of the symptoms will be delayed. Some individuals may get an asthma attack in under 24 hours of being exposed. Others may not show any signs for months or years, depending on their individual circumstances. (*Types of Asthma: Classification and Severity*, n.d.)

Chapter 4

Natural History of Asthma

4.1 Natural History Of Persistent Asthma

China is home to the earliest known reference of the respiratory distress, which is characterized by "noisy breathing" and was first recorded there around 2600 BC. When a man's lungs pant as a result of his labor, according to the Babylonian "Code of Hammurabi," he is suffering from exhaustion. (1792-1750 BC) Hippocrates (400 BC) created the term "asthma" to describe a condition characterized by panting and respiratory pain . In addition to uncovering the relationship among the environment and the respiratory disease, he is credited with establishing a link between climate and geographic location and this illness.

(*History of Asthma - Allergy & Asthma*, n.d.)

Pliny the Elder (about at 50 AD) saw pollen as a reason of respiratory discomfort and proposed for the use of "ephedra" mixed in the red wine as an asthma remedy. Sadly, he also suggested that having a drink of wild horse blood and also the eating of 21 honey-soaked millipedes might be beneficial. As an asthma cure, the Jewish Talmud (around 200-500 AD) advocated "drinking 3 weights from hiltith," a resin from the carrot family. Regarding asthma, Saladin's doctor and also a Jewish philosopher Maimonides (1135-1204 AD) administered treatment to the Egyptian's son.

(*History of Asthma - Allergy & Asthma*, n.d.)

4.1.1 Children

When children have severe asthma, they are at increased risk of developing other health problems. Chronic asthma in children increases the likelihood of unfavorable outcomes such as medication-

related health consequences, life-threatening exacerbations, and also a worse QuOL. When treating asthma which is kind of therapy resistant, it is essential to select between this condition and difficult-to-treat-asthma caused by comorbidities. One of the most prevalent problems that must be ruled out before the diagnosis is poorly medication-adherence. Other problems to rule out include poor medication technique and inaccurate asthma diagnosis. Exacerbations and chronic symptoms of difficult-to-treat asthma are far more prevalent, but they may be controlled if the underlying comorbidities are identified and treated appropriately. (Haktanir Abul & Phipatanakul, 2019)

4.1.2 Adults

Globally, around 300 million individuals suffer with asthma, with 7.5 percent that counts for adults in the USA being affected. Airway inflammation, fluctuating airflow restriction, and hyperresponsiveness of the bronchial mucosa are all characteristics of asthma. The diagnosis of the asthma is made clinically, accordance to the history and physical test being important factors; however, objective tests, like pulmonary-function testing, can be utilized to help in the identification of the condition. Asthma is connected with a number of concomitant conditions, such as rhinitis, sinusitis, disease of gastroesophageal reflux , obstructive-sleep apnea, and also depression.(Wenzel, 2005)

4.1.3 Geography

Asthma is a widespread condition, but its impact is felt most strongly in Alameda County, at which incidence of asthma hospitalizations is 20.3 per 10,000, about double the rate for the entire state. Regional variation in hospitalization rates may be influenced by a variety of factors including

healthcare access, socioeconomic status, zoning and transportation patterns, quality of housing, and geographical variance. (Shaheen, 2013)

Chapter 5

Biomarkers Associated With Inflammation

It is possible to identify eosinophilic inflammation by the use of a number of biomarkers. The merits and downsides of tje noninvasive biomarkers will be discussed in further depth in the next section. The b ronchoalveolar lavage or the biopsy samples should not be used on a routine basis since they are inconvenient and may result in further difficulties. Current study uses periostin, which has not been licensed for clinical use as of yet, however current clinical trials are looking at whether it can be used in predicting response to the biologics . (Oberle & Mathur, 2017)

5.1 Eosinophils count in the bloodstream

Absolute blood eosinophils levels/amounts are a particularly promising biomarker for the identification of Th2 high condition because of the familiarity, its ease of using, and the fact that it is noninvasive. Individuals who are at elevated risk of the asthma exacerbations can be identified using this technique. It is expected that an AEC greater than 300–400 cells/ml will predict responsiveness to corticosteroids, despite the fact that the cut-off value has not been found. However, both the sensitivity and the specificity of blood eosinophil counts are inferior than those of sputum eosinophils. This is most probably explained by their attraction for tissues, which causes their circulating levels/concentrations to be decreased . It has been suggested that an approach that makes use of numerous biomarkers may be more effective than a strategy that makes use of a single biomarker. Despite the fact that blood eosinophils do not have the detection/diagnosis accuracy of sputum, researchers feel that they still have a place in clinical practice. The use of a blood eosinophil-based therapy method has not been studied in major trials to yet, but one small pilot research has revealed that it may be beneficial. In order to predict therapeutic responsiveness to anti-ILn-5 treatment, eosinophils within the blood are the biomarkers of choice. (Oberle & Mathur, 2017)

5.2 FreNO

It is thought that exhaled-NO is created through the inducible NO-synthase pathway and that serves as a biomarker for the Th2 inflammation. It is indeed a noninvasive test which is quite straightforward, easy to do, and does not require any special equipment. Values larger than 50 parts per billion (ppb) are regarded extremely likely to react/respond to corticosteroids, whilst values fewer than 25 parts per billion (ppb) are regarded less likely to respond/react . Some

research have demonstrated the usefulness of FreNO in identifying asthma-control deterioration and also the exacerbation risk. Despite the fact that FreNO is indeed a proxy biomarker for the airway eosinophilia, it does not have the sensitivity and also the specificity of sputum. It is true that interpretation of data might be problematic in the presence of several confounding factors, such as cigarette smoke and recent InCS or OrCS exposures, among many patients . The findings of a recent meta-analysis, which showed a tendency toward a decline in exacerbations when a FreNO-based treatment plan was put side to side with a typical therapeutic strategy, were restricted by high heterogeneity between studies.(Oberle & Mathur, 2017)

Chapter 6

Biologics

6.1 Biologics that are in the current use

6.1.1 Anti-IGE

6.1.1.1 Name : Omalizumab

Omalizumab is now a monoclonal antibody that has been authorized by the European Medicines Agency (EMA) to attach and deactivate IGE. Associated with severe persistent allergic asthma,patients those who seem to have a positive skin test or in vitro reactions to a longstanding aeroallergen and fairly regular daytime symptoms or night-time awakenings, and who have had numerous recorded severe asthma exacerbations even after daily high-dose inhaled-corticosteroids and also a long-acting inhaled beta2-agonist , omalizumab as an add-on therapy for patients aged 6 years and older. Reduced lung function (FEV1 less than 80%) is also necessary for individuals under the age of 12 years. (Loureiro et al., 2018)

6.1.1.2 MeOA(Mechanism Of Action)

Knowing that allergens access the airways and are exposed to T lymphocytes via dendritic cells, we may expect the cell-mediated immune response to be initiated, notably the development and migration of Th cells. In addition to producing IGE antibodies, Th-2 cells also trigger B-cells to make other chemicals. Once IGE is set to release from B - cell, this then binds towards the FcεRI just on exterior of mast cells and basophils, where it is cross-linked via allergen. This causes degranulation as well as the release of prostaglandins, leukotrienes, histamine, proteases,

exoglycosidases, proteoglycans, and cytokines, which results in the onset of the initial allergic response. A portion of FcεRI is also detected on dendritic cells, wherein their interaction between IGE and allergen leads to the development of the late-phase allergic response that are related to Th2 cells and eosinophils. As a result of the revelation that IGE plays a major role in allergic asthma, researchers have begun investigating the therapeutic benefits that can be gained by targeting this specific antibody. (Humbert et al., 2014)

Omalizumab blocks IGE from attaching itself toward its high affinity receptor (FcεRI) onto both mast cells as well as basophils, hence dampening the release of proinflammatory mediators and blunting overall downstream allergic responses. Omalizumab also has the effective impact of downregulating the activation of the IGE-receptors on mast cells, that further decrease inflammation. As well as reducing exacerbations throughout prime viral seasons, clinical trials have also shown that omalizumab can also increase interferon- produced in response of rhinoviruses, indicating the prospect of additional anti-viral MeOA. (McGregor et al., 2019)

6.1.1.3 Study Of Efficacy

Omalizumab has been used therapeutically for the purpose of curing allergic asthma for over 15 years and it has showed promising results in several randomized control studies (RCTls). During 2014, a Cochrane review of 25 RCTlSs among individuals having moderate-to-severe allergic asthma discovered that omalizumab, when was put side by side with placebo, decreased asthma exacerbations by around 25%, lowered hospitalizations, as well as enabled for a lowering in InCS regimen. A few research have found a little enhancement in lung functions, but many have not. There seems to be no convincing evidence to indicate a decrease in OrCS in people that are being treated with omalizumab. Several of the previous trials using omalizumab were all in individuals

with moderate allergic asthma; nevertheless, following trials in severe allergic asthma have shown similar effectiveness. Real-world trials have shown that omalizumab reduces exacerbations and hospitalisation. Initiatives in order to actually understand in a better way, particular patient factors that might indicate which individuals might benefit the most from omalizumab are continuing. Retrospective studies indicate that individuals with elevated eosinophil counts as well as high-exhaled NO levels who take omalizumab had a huge lowering of asthma exacerbation. This variation may indeed be related to a larger number of exacerbations in individuals with greater T2 biomarkers, enabling for a significant decrease with omalizumab. As a result, even individuals with low T2 biomarker readings that fit for omalizumab could gain benefit from its usage. A recent pragmatic study of omalizumab indicated equivalent effects in T2 high and low patients (AEC ≥300 cells/L and FreNO< or ≥25 ppb). Furthermore, investigations have shown that omalizumab had a similar effect in individuals with IGE amounts both elevated and lessened than the officially permitted level of 30-700 IU/mL in the U. S.. Moreover, in a proof-of-concept pilot study, omalizumab reduced (FcεRI) expression onto basophils among patients having nonatopic asthma, indicating a prospective function for omalizumab for paitents non-allergic phenotype.. (McGregor et al., 2019)

6.1.1.4 Safety Study,Dosing,Indications

With in U. S., omalizumab is authorised for patients under the age than 6 years old with moderate to severe persistent asthma, symptoms not sufficiently kept in check via InCS , positive allergy testing, and a serum total IGE amount between 30 and 1300 IU/mL for patients 6-11 years old and between 30 and 700 IU/mL for patients younger than 12 years old. In general, omalizumab is subcutaneously delivered each two to four weeks, with the frequency, dose, and length of administration regulated by the person's body mass as well as IGE value before therapy. This is

not recommended to go for monitoring the IGE amounts throughout treatment. As per the XPORT experiment outcomes, a 3-6 months trial needs to be done to evaluate therapeutic response, and medication must be maintained indefinitely if an individual has a good outcome. With omalizumab, which is typically well tolerated, there is a 0.1-0.2 percent chance of anaphylactic reaction. Even though the possibility of anaphylaxis is thought to be low, the Fda has approved a BBW for the medication, and that should only be administered at such a hospital setting which is enough-prepared to handle anaphylaxis if this occurs. Patients should be observed for 120 minitues following the first three injections and not only that, even for half-an-hour after every subsequent therapy.(McGregor et al., 2019)

6.1.2 Anti-ILn-5

Eosinophil generation and recruitment are directly influenced by ILn-5. During eosinophilic asthma, biologic therapies that suppress ILn-5 have indeed been proven to enhance control, minimize exacerbations, and decrease eosinophil counts. (Oberle & Mathur, 2017)

6.1.2.1 Mepolizumab

Mepolizumab is an IgG1-humanized monoclonal antibody (mAb) that suppresses ILn-5. This was the first Anti-ILn-5 medication authorized by the US FDA in November 2015 for people aged 12 and up who have uncontrolled eosinophilic asthma (AEC ≥150 cells/ml) despite receiving the best available treatment.(Oberle & Mathur, 2017)

In case of individuals that have severe asthma that have an eosinophilic phenotype (eosinophil count greater than or equal to 150 cells/mL at screening or greater than or equal to 300 cells/mL within 12 months before enrollment), mepolizumab has been currently licensed by Food and Drug Administration (FDA) as an add-on maintenance therapy . Efficacy and effectiveness of

mepolizumab in the treatment of severe asthma and eosinophilia has been demonstrated in several clinical studies. (Blaiss et al., 2017)

6.1.2.1.1 MeOA(Mechanism Of Action)

The presence of an eosinophilic phenotype in patients with moderate-to-severe asthma, which is defined by a rise in sputum and/or amount of blood eosinophils counts even after therapy with corticosteroids, increases the likelihood of repeated exacerbations in people with the condition. Because ILn-5 is the prime cytokine associated with recruiting, activation, as well as persistence of eosinophils, blocking this pathway has a significant effect on Inflammatory eosinophilic airway inflammation and it can be reduced using Anti-ILn-5 biologics . Mepolizumab works by inhibiting ILn-5, stopping it from attaching towards its receptor located on eosinophils and so alleviating the downstream eosinophilic inflammation . (McGregor et al., 2019)

6.1.2.1.2 Study Of Efficacy

In clinical trials, mepolizumab was found to be effective in individuals with uncontrolled eosinophilic asthma that had elevated sputum (>3 percent) or elevated AEC (150 or 300 cells/L). Mepolizumab has indeed been observed in various RCTls to lessen asthma exacerbations, boost lung function, enhance asthma control, and lower the use of OrCS. Throughout the SIRIUS trial, therapy using mepolizumab resulted in a 50 percent reduction in OrCS dose among patients having eosinophilic asthma who were taking chronic OrCS. Such corticosteroid-sparing effect took place while also preserving the effects of fewer exacerbations (32 percent) and better asthma control, which were previously seen. The effect of mepolizumab on pulmonary function has been less well-documented. Some trials showed an improvement in FEV1, but one of the largest trials, the DREAM trial, showed no statistically significant increase in FEV1 with mepolizumab.

According to a recent Cochrane study, individuals with eosinophilic asthma who were treated with mepolizumab saw a 50% reduction in asthma exacerbations and a minor increase in FEV1 of 110 mL when compared to those who were treated with placebo. As evaluated by the St. George's Respiratory Questionnaire(SGRQ), mepolizumab was associated with a clinically and statistically significant improvement in quality of life (QuOL) .Lacking of the clinical response to omalizumab may not always predict the lacking of clinical response to mepolizumab. (McGregor et al., 2019)

6.1.2.1.3 Safety Study,Dosing,Indications

Mepolizumab is now licensed for the treatment of people below the age of 12 who have severe asthma as well as with an eosinophilic phenotype. RCTls have shown that individuals that are having a count as few as 150 cells/L, specifically those who are on chronic OrCS, may benefit from the treatment, despite the fact that the FDA has not imposed an AEC requirement . A dose of 100milligrams of mepolizumab is delivered subcutaneously each 4 weeks. If a clinical response is shown during 4 months, therapy using mepolizumab should then be maintained indefinitely. A significant safety profile has been found for mepolizumab that is quite identical to placebo . Patients under 50 years of age who have not yet received their first zoster vaccine (ideally a recombinant rather than a live virus) should get it 4 weeks before starting their medication. At an increasing doses of 300mg per 4 weeks, mepolizumab is also licensed for treating eosinophilic- granulomatosis with polyangiitis (EGPA). (McGregor et al., 2019)

6.1.2.2 Reslizumab

Reslizumab is an IgG4-humanized monoclonal antibody that counteracts circulating ILn-5 (IL-5) . It was authorized by the US Food and Drug Administration (FDA) in March 2016 for

patients having age of 18 and also older that are having severe eosinophilic asthma who had an AEC of minimum 400 cells/ml. (Oberle & Mathur, 2017)

6.1.2.2.1 MeOA(Mechanism Of Action)

Both Mepolizumab and this drug have the same MeOA. A similar cytokine is targeted by this as well. Reslizumab is a humanized monoclonal antibody. In addition, it binds selectively to ILn-5, prohibiting the biological impacts of the cytokine, such as the recruiting and activating the human eosinophils, from taking place.(Ibrahim et al., 2019)

6.1.2.2.2 Study Of Efficacy

Reslizumab has repeatedly been proven to lower AEC, minimize asthma exacerbations, and enhance lung function in people having uncontrolled eosinophilic-asthma in multiple RCTls. Reslizumab's OrCS-sparing impact has yet to be studied.In one study it's observed that Reslizumab had no significant effect on lung functions among the patients with AEC less than 400 cells/micro-L , emphasizing the necessity of choosing an eosinophilic phenotype. Reslizumab decreased asthma exacerbations nearly half of the previous , raised FEV1 by 110 mL above placebo, and enhanced QuOL, according to a current Cochrane study. (McGregor et al., 2019)

According to Ibrahim et al. (2019) , Since about the beginning of 2017, 26 patients having asthma have been treated with reslizumab at their facility. The results of their two-year study revealed a substantial drop in asthma exacerbations (88 percent reduction in those patients

that've finished the 2 years of receiving treatment). Moreover, reslizumab exhibited a steroid-sparing effect, resulting in considerable decreases in the amount of steroid required for maintenance. This response was noticed during 12 weeks of starting therapy and was consistent with in patient groups who had accomplished two years of therapy at the time of the study. Whereas slight improvements in the lung function were observed in patients treated with resluzimab after three months, such improvements were still not statistically significant; however, data from patients treated with resluzimab after one and two years revealed statistically significant improvements in lung capacity (mean improvement in FEV-1 percent of predicted value was 11.9 percent at 1 year and 12.1 percent at 2 years). This shows that the greatest improvements at FEV-1 occur within the first 12 months of therapy. Nonetheless, it was sustained after that.

6.1.2.2.3 Safety Study,Dosing,Indications

Reslizumab has been authorized as an add-on medication for patients under the age of 18 who have severe eosinophilic-asthma (AEC greater than or equal to 400 cells/L). Reslizumab has been the only one biologic that is administered intravenously (IV) utilizing a weight-based dosing regimen at a dose of 3 mg/kg each four weeks. The use of weight-based approach of dosing may have significant benefit over the use of predetermined/fixed doses. Reslizumab is quite well tolerated, with side effects that are comparable to those observed with in placebo group. Moreover, three occurrences of anaphylaxis were reported throughout RCTls, and for this , reslizumab is accompanied by an FDA BBW on the label..(McGregor et al., 2019)

According to Ibrahim et al. (2019) , Since about the beginning of 2017, 26 patients having asthma have been treated with reslizumab at their facility . Overall, patients appear to be

responding well to Resluzimab and it is quite well-tolerated . Exhaustion and increases in creatinine-kinase levels are perhaps the most commonly reported adverse effects (Mean creatinine kinase level rose from 94.1 U/L pretreatment level to 184.7 U/L throughout 3 months of therapy and 160.5 U/L over 1 year). Their institution's typical level for creatine kinase = (40–180 U/L).

6.1.2.3 Benralizumab

Benralizumab is a monoclonal antibody which inhibits the ILn-5 receptor-a, and it is now under clinical investigation and development (Table 2). It causes an immediate, quick, and pretty much complete decline of eosinophils through antibody-dependent-cellular-cytotoxic activities facilitated by NK cells. Previously, It has been linked to a reduction in the airway eosinophils (300 cells/mL), as well as to redcution of some of the other ILn-5 receptor-bearing-cells. (Blaiss et al., 2017)

6.1.2.3.1 MeOA(Mechanism Of Action)

Benralizumab works through a somewhat different MeOA. This is an mAb which attaches towards the alpha-subunit of the ILn-5 receptor on eosinophils as well as basophils, inhibiting the attachment of ILn-5 towards the receptor and the consequent recruiting and activating of eosinophils. Moreover, afucosylation which is performed by of benralizumab mAb improves its capacity to interact with FcRIIIa onto NK cells, inducing eosinophil aggregation(surrounding the eosinophils) and ADCMC, as well as eosinophil death accompanied by macrophage-phagocytosis.. (McGregor et al., 2019)

6.1.2.3.2 Study Of Efficacy

Benralizumab, like all the other Anti-ILn-5 biologics, has indeed been found to decrease the number of asthma exacerbations that occur and to enhance lung function/capacity in patients having uncontrolled eosinophilic-asthma . According to the Cochrane review that took place in 2017, individuals given benralizumab were observed and it was seen that a significant decrease in asthma exacerbations, independent of previous AEC. Benralizumab, on the other hand, had the highest impact in individuals with AEC counts less than or equal to 300 cells/L. Additionally, enhancements in lung function/capacity and QuOA were shown to be statistically significant just in the larger eosinophil group. During the ZONDA trial, this was discovered that benralizumab may considerably reduce OrCS usage by 75 percent among patients taking long-term OrCS at AEC 150 cells/L, even while lowering annual asthma-exacerbations approximately 70%. Benralizumab seems to be similarly effective regardless atopy. (McGregor et al., 2019)

6.1.2.3.3 Safety Study,Dosing,Indications

Benralizumab is licensed for the treatment of kids under the age of 12 who have uncontrolled eosinophilic-asthma (AEC greater than or equal to 300 cells/L) . Benralizumab is delivered subcutaneously in a dose of 30 mg each four weeks for about the first 3 doses as part of the induction phase , and then every eight weeks for about the remainder of the treatment as part of the phase of maintenance . To determine whether or not a treatment is effective, a 4-month study should be conducted. Benralizumab is typically well tolerated, however it has been associated with severe hypersensitivity events such as anaphylaxis, urticaria, angioedema, in some patients.. (McGregor et al., 2019)

6.1.3 Anti-ILn-4 Therapy

6.1.3.1 Dupilumab

Dupilumab is a humanized monoclonal-antibody that works against the receptor for ILn-4 . ILn-4 and ILn-13 both bind with this receptor, which means that dupilumab tends to inhibit both signaling pathways. (Côté et al., 2020)

6.1.3.1.1 MeOA(Mechanism Of Action)

The results of targeting or aiming for ILn-4 or ILn-13 individually have been unsatisfactory, owing to the fact that focusing either one of these previously mentioned cytokines does not stop airway inflammation. Dupilumab binds to the ILn-4 receptor and inhibits the signaling that are executed by both the ILn-4 and ILn-13, two important cytokines that enhance IGE synthesis and inflammatory cell recruiting, as well as increasing goblet-cell hyperplasia & modifying airway hyperresponsiveness as well as remodel. (McGregor et al., 2019)

6.1.3.1.2 Study Of Efficacy

Dupilumab has indeed been proven to minimize asthma exacerbations, enhance lung function/capacity in a short period of time, and lessen OrCS usage in patients with moderate-to-severe asthma, while simultaneously reducing levels of T2 inflammation (FeNO, ThARC, eotaxin-3, and IGE) . The advantages of dupilumab appeared stronger in patients having elevated baseline AEC and also FreNO levels than in those with lower baseline values . Dupilumab was shown to considerably lower OrCS use by 70 percent of the overall in individuals, with almost half of patients managing to completely terminate OrCS treatment. Such OrCS usage declines occurred when exacerbation rates were reduced by 60 percent and lung function was improved . It has been shown that dupilumab improves outcomes in individuals having symptomatic chronic-rhinosinusitis and also nasal polyposis. (McGregor et al., 2019)

6.1.3.1.3 Safety Study,Dosing,Indications

According to Grayson et al. (2018) , The Sino-Nasal-Outcome-Test–22 scores of patients receiving 300 miliograms of dupilumab every two weeks showed statistically significant progress at the time period of 24 weeks compared to placebo. When compared to individuals who received a placebo, those who received dupilumab were observed improvements in overall lung function and the annualized percentage of excerbatuions of severe asthma . Patients having perennial allergic rhinitis who received 200 milligrams of dupilumab each 2 weeks across a 24-week period showed no statistically impotant/significant changes at nasal symptom management, lung function/capacity , or the annualized rates of the severe asthma. Using 300 miligrams of dupilumab as somewhat of an add-on therapy in case for a moderate - to high-dose InCS and also LoABA for patients having perennial allergic rhinitis, those data discovered that nasal symptom control/management, lung function/capacity , and exacerbation rates/frequencies of asthma were all improved.

In contrast to the Anti-ILn-5 RCTls ,baseline FreNO was found that it's somehow predicts dupilumab's clinical response . It is not unexpected that FreNO was found to be a marker that predicts the clinical response to dupilumab because ILn-4 and also ILn-13, through STAT6 phosphorylation process, regulate both iNOS and also the MUC-5AC gene, as well as mucus formation. In terms of safety, dupilumab does indeed have a positive profile, with the most often reported adverse effects that include reaction at the site of injection and transitory blood eosinophilia. Dupilumab has been licensed by the Food and Drug Administration (FDA) for the therapy of atopic-dermatitis, and now it has been licensed for asthma treatment.(McGregor et al., 2019)

6.2 Biologics That Are Emerging

6.2.1 Anti-ThSLP Therapy

6.2.1.1 Tezepelumab

Tezepelumab is a humanized monoclonal antibody under research for its ability to block the function of thymic stromal lymphopoietin (ThSLP). ThSLP is a member of the cytokine family known as " alarmins ‘’ ,which are epithelial-derived cytokines that are also implicated in the T2 inflammatory pathway

6.2.1.1.1 MeOA(Mechanism Of Action)

An epithelial cell–derived cytokine, thymic stromal lymphopoietin (ThSLP), regulates type 2 responses through its activity on innate immune cells, T cells, and B cells. Tezepelumab binds to TSLP and suppresses type 2 inflammation. That’s how it renders its pharmacological action. (Grayson et al., 2018)

6.2.1.1.2 Study Of Efficacy

To demonstrate the efficacy of tezepelumab ,a proof-of-concept allergen challenge was done. Here 700 milligrams was given every four weeks for twelve weeks among individuals with mild-allergic

asthma, and also inhaled allergen challenge was delivered at the start of the research and again after six and twelve weeks. The decreases in FEV1 following an allergen challenge during week Six and week Twelve were much less with tezepelumab than with placebo, according to the findings (34 percent and 46 percent , respectively). Additionally, individuals who received tezepelumab experienced substantial reductions in the amounts of eosinophils in their blood and sputum during pre and post phase of the allergen challenge. Additionally, FreNO levels decreased during the research, and elevations in FreNO following exposure to allergens were dramatically lowered . Across a 52-week period, individuals having moderate-to-severe uncontrolled asthma were treated with tezepelumab at doses of 70 milligrams each four weeks, 210 milligrams each four weeks, or 280 mg every 2 weeks, or a placebo every 2 weeks, according to the findings of the phase-2b research. Tezepelumab was quite well/nicely tolerated, and the annualised rate/frequencies of the asthma exacerbation with in tezepelumab divisions were considerably lower than those within the placebo groups (by 61 percent , 71 percent and 66 percent , respectively). B lood eosinophil levels of the patients at the time of enrollment had no effect on the outcomes, which were indistinguishable. Tezepelumab medication enhanced pre-bronchodilator FEV1 during week-52 compared to placebo during the 1st month and gradually developed throughout the study. As a result of an analytical examination of phase-2b results, it was shown that tezepelumab can lower rate/frequencies of annualised asthma exacerbation regardless of the patient's initial blood eosinophil counts, FreNO value, and serum concentrations of IGE, ILn-5, ILn-13, or ThARC. Furthermore, quantities of these proinflammatory biomarkers and cytokines were lowered as early as four weeks following treatment beginning, and also the declines were subsequently maintained across the 52-week treatment period, indicating that the therapy was effective early on. When considered as a whole, these data shows that tezepelumab

has wide inhibitory activity on several T2-inflammatory mediators of the asthma, implying that anti-ThSLP medication may be useful in individuals with various inflammation-phenotypes . (Porsbjerg et al., 2020)

As previously stated, since ThSLP is thought to activate T2 inflammation among individuals having steroid-refractory asthma by both the Th-2 and ILnC2 cells, inhibiting ThSLP using tezepelumab may be useful in reducing inflammation in these patients. The fact that tezepelumab was found beneficial in patients having low blood eosinophils and also low FreNO suggests that it can be useful in people having the T2-low asthma, according to the findings. In contrast, the biologics that target T2 pathways, including Anti-ILn-4R as well as Anti-ILn-5, have been proven to be less effective in patients with low vs high eosinophil counts/levels , according to the research. To far, there has been no confirmation that tezepelumab is efficacious in individuals with T2-low asthma. This will rely over how T2-low asthma is characterized in further clinical studies, which will be based on biomarkers. (Porsbjerg et al., 2020)

6.2.1.1.3 Future Studies

Numerous clinical studies evaluating the effectiveness and also the safety of tezepelumab in various patient groups are now underway, with findings expected to be presented in the near future (table 3). 2 phase-two studies (NCT02698501 and NCT03688074) and 2 phase-three studies are currently underway, with one looking(NCT03406078) at the efficacy/effectiveness and safety profile of tezepelumab in lowering OrCS usage in adults having OrCS-dependent asthma, and the other looking at the efficacy/effectiveness and also the safety of tezepelumab among adults and adolescents having severe, uncontrolled asthma (NCT03347279). Another anti-ThSLP

monoclonal-antibody component, CSJ117, is being tested in phase 1 (NCT03138811), although findings have not yet been made public.(Porsbjerg et al., 2020)

6.2.2 Anti-ILn-33

Some ILn-33 or ST2- targetting monoclonal antibodies are under clinical development (table 3), however the findings of these investigations are not yet disclosed at peer-reviewed publications. RG6149/MSTT1041A, also known as AMG282, is being studied in a twelve - month phase-2b investigation among patients having uncontrolled severe-asthma. The key end measure is the exacerbations rates/frequencies (NCT02918019). In a twelve-week phase-2a study involving patients having moderate-to-severe asthma, REGN3500 (SAR440340) was tested both alone/individual and also in a combination with dupilumab, and the results were promising (NCT03387852), but I they have not yet been published at any peer-reviewed journal.There were no significant differences in outcomes between the Anti-ILn-33-antibody and dupilumab monotherapy for the main goal of minimizing 'loss-of-asthma-control' events versus placebo. Furthermore, when REGN3500 and dupilumab were used together, there was no evidence of an improved advantage as compared to dupilumab separately . There've also been 2 previous phase-1 trials of REGN3500 that have been concluded (NCT03112577, NCT02999711). Recently, the drug etokimab (ANB020) was tested in a proof-of-concept phase-2a investigation among adults having severe eosinophilic-asthma, with the primary result being a shift at blood eosinophil counts/levels (NCT03469934). In a phase-2a investigation among adults having moderately severe-asthma, GSK3772847 (CNTO7160) has finally completed and it does have a primary outcome and that is being loss of the asthma-control events during week-16 (NCT03207243). A phase-2b study consisting of 28-weeks period in patients having moderate-to-severe asthma who also have allergic-fungal airway disease is now underway,

with the primary findings being alteration of the counts of blood eosinophil from the baseline and also FreNO value at week-13(NCT03393806). (Porsbjerg et al., 2020)

6.2.3 Anti-ILn-25

Despite the fact that ILn-25 tends to play a pivotal role throughout allergic inflammation, notably at the period of virus-induced asthma exacerbations (mentioned earlier), none clinical studies with antiI-IL-25 antibodies seem to be currently in progress. (Porsbjerg et al., 2020)

Chapter 7

Future Aspects Of Biologics Therapy

Following improvements in understanding or the knowledge about the asthma immunopathogenesis , other inflammatory -pathways have already been recognized as potential therapeutic targets , and the development of new biologics is underway. Researchers are investigating numerous upstream targets that are related with T2 inflammation, including ILn-25, ILn-33, and ThSLP, in addition to the downstream-targets that are associated with T2 inflammation that are now U.s. FDA approved biologics (previously stated). It is now being investigated if biologics and also small-molecule antagonists that target kinases (for example, JAK pathways) which are downstream of those T2-cytokines would be effective or not. Alternative means of administration for biologic medicines, other than subcutaneous or intravenous injection, are being studied. The plasma concentrations of biologics following IV delivery are much greater than that of BAL concentrations . Scientists are investigating the use of nebulized biologic treatment in order to enhance drug concentration within terminal bronchioles while simultaneously minimizing systemic toxicity. A recent animal research investigating the usage of a nebulizer for delivering fragments of Anti-ILn-13 monoclonal antibody towards the terminal-bronchioles indicated a decrease at allergic- airway response and also it's quite well tolerated. (McGregor et al., 2019)

Biologics also do have the potential to act like a disease-modifying agent. Elevated subepithelial reticular basement membrane thickness and airway smooth muscle mass, as well as angiogenesis and also goblet cell hyperplasia, all are observed in the pathogenesis of asthma and ultimately lead to irreversible/permanent lung function loss. It occurs for the airway remodeling . It's been

reported that therapy using an Anti-ILn-5 antibody results in a decrease at the integration of proteoglycans into the human airway-wall, leading to the hypothesis that biological treatments might serve as disease modifying agents via inhibiting airway remodeling. Furthermore, it has been demonstrated that treating a murine asthma model using an Anti-ILn-5 antibody inhibited the development of the subepithelial fibrosis.(Pavord et al., 2019)

According to Pavord et al. (2019) , throughout their forum, the experts explored the potential of a research aiming to investigate the impact of long-term therapy with biologics on the airway remodeling in patients with severe asthma. This study/investigation would also be useful in the case of the identification of the biomarkers that are indicative of airway remodelling and that are clinically significant for the monitoring of therapy responses. It is anticipated that such a research would reveal if biologics have the ability to serve as a disease modifiers or modifying agent , which has not yet been shown.

Chapter 8

Conclusion

The majority of asthma patients, luckily, do not require a biologic medicine if they are taking their normal controller drugs as directed. The identification of the eosinophilic-airway inflammation as a curable feature has paved the path for the development of biologic therapies for this particular patient group. Anti-ILn-5 mAbs are the treatment of choice in individuals who suffer from severe asthma and whose luminal constriction and asthma intensity/severity are mostly mediated by eosinophils . An anti-ILn-4R mAb may be the treatment of choice in individuals whose luminal blockage and severity/intensity may be caused via variables such as mucus formation, the eosinophils, contraction of the smooth muscles and also remodeling. Furthermore, individuals with asthma that is obviously led by a previous history of allergies (rather than simply by a raised IGE level/concentrations) are suitable for anti-IGE treatment; however, anti-ILn-5 biologics may also be useful in some of these kinds of patients. While there is inadequate data to support anti-IGE medication in the case of severe asthma that need maintenance OrCS, yet there is enough evidence to suggest that allergies might not be the root cause of the patient's requirement for OrCS. New biologics that enhance the situation in patients having non-eosinophilic or T2-low conditions are urgently needed to be studied and developed. Alarmins are upstream mediators that are activated earlier throughout the inflammatory response and orchestrate wide T2 inflammatory effects. Targeting alarmins is a potential alternative method which may be beneficial in a larger patient group. Further investigation into the function of alarmins in the process of asthma development will help us to better understand the severity/intensity of the condition and also the heterogeneity of response to present therapies. Finally, the idea of initiating

biologics early in the course of a disease's development is fascinating and should be investigated further.

Chapter 9

Reference

Asthma Attack Symptoms and Early Signs of Asthma. (n.d.). Retrieved February 20, 2022, from https://www.webmd.com/asthma/asthma-symptoms

Blaiss, M. S., Castro, M., Chipps, B. E., Zitt, M., Panettieri, R. A., & Foggs, M. B. (2017). Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma. *Annals of Allergy, Asthma and Immunology*, *119*(6), 533–540. https://doi.org/10.1016/j.anai.2017.09.058

Bullone, M., Carriero, V., Bertolini, F., & Ricciardolo, F. L. M. (2019). *Effect of bronchial neutrophilia on airway remodeling in asthma*. PA3864. https://doi.org/10.1183/13993003.congress-2019.pa3864

Cell biology of disease: The cell biology of asthma. (n.d.). Retrieved February 25, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050726/#!po=5.17241

Chapman, D. G., & Irvin, C. G. (2015). Mechanisms of Airway Hyperresponsiveness in Asthma: The Past, Present and Yet to Come. *Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology*, *45*(4), 706. https://doi.org/10.1111/CEA.12506

Cockcroft, D. W. (2018). Environmental Causes of Asthma. *Seminars in Respiratory and Critical Care Medicine*, *39*(1), 12–18. https://doi.org/10.1055/S-0037-1606219

Côté, A., Godbout, K., & Boulet, L. P. (2020). The management of severe asthma in 2020. In *Biochemical Pharmacology* (Vol. 179). Elsevier Inc. https://doi.org/10.1016/j.bcp.2020.114112

Elias, J. A., Zhu, Z., Chupp, G., & Homer, R. J. (1999). Airway remodeling in asthma. *Journal of Clinical Investigation*, *104*(8), 1001–1005. https://doi.org/10.1172/JCI8124

Grayson, M. H., Feldman, S., Prince, B. T., Patel, P. J., Matsui, E. C., & Apter, A. J. (2018). Advances in asthma in 2017: Mechanisms, biologics, and genetics. *Journal of Allergy and Clinical Immunology*, *142*(5), 1423–1436. https://doi.org/10.1016/j.jaci.2018.08.033

Haktanir Abul, M., & Phipatanakul, W. (2019). Severe asthma in children: Evaluation and management. *Allergology International : Official Journal of the Japanese Society of Allergology*, *68*(2), 150–157. https://doi.org/10.1016/J.ALIT.2018.11.007

History of Asthma - Allergy & Asthma. (n.d.). Retrieved February 24, 2022, from https://allergyandasthma.com/articles/history-of-asthma/

Humbert, M., Busse, W., Hanania, N. A., Lowe, P. J., Canvin, J., Erpenbeck, V. J., & Holgate, S. (2014). Omalizumab in Asthma: An Update on Recent Developments. *Journal of Allergy and Clinical Immunology: In Practice*, *2*(5), 525-536.e1. https://doi.org/10.1016/j.jaip.2014.03.010

Ibrahim, H., O'Sullivan, R., Casey, D., Murphy, J., MacSharry, J., Plant, B. J., & Murphy, D. M. (2019). The effectiveness of Reslizumab in severe asthma treatment: A real-world experience. *Respiratory Research*, *20*(1). https://doi.org/10.1186/s12931-019-1251-3

Loureiro, C. C., Amaral, L., Ferreira, J. A., Lima, R., Pardal, C., Fernandes, I., Semedo, L., & Arrobas, A. (2018). Omalizumab for severe asthma: Beyond allergic asthma. In *BioMed Research International* (Vol. 2018). Hindawi Limited. https://doi.org/10.1155/2018/3254094

McGregor, M. C., Krings, J. G., Nair, P., & Castro, M. (2019). Role of biologics in asthma. *American Journal of Respiratory and Critical Care Medicine*, *199*(4), 433–445. https://doi.org/10.1164/rccm.201810-1944CI

Mims, J. W. (2015). Asthma: Definitions and pathophysiology. *International Forum of Allergy and Rhinology*, *5*, S2–S6. https://doi.org/10.1002/alr.21609

Oberle, A. J., & Mathur, P. (2017). Precision medicine in asthma: The role of bronchial thermoplasty. In *Current Opinion in Pulmonary Medicine* (Vol. 23, Issue 3, pp. 254–260). Lippincott Williams and Wilkins. https://doi.org/10.1097/MCP.0000000000000372

Pavord, I., Bahmer, T., Braido, F., Cosío, B. G., Humbert, M., Idzko, M., & Adamek, L. (2019). Severe T2-high asthma in the biologics era: European experts' opinion. In *European Respiratory Review* (Vol. 28, Issue 152). European Respiratory Society. https://doi.org/10.1183/16000617.0054-2019

Pelaia, G., Vatrella, A., Gallelli, L., Renda, T., Cazzola, M., Maselli, R., & Marsico, S. A. (2006). Respiratory infections and asthma. *Respiratory Medicine*, *100*(5), 775–784. https://doi.org/10.1016/J.RMED.2005.08.025

Porsbjerg, C. M., Sverrild, A., Lloyd, C. M., Menzies-Gow, A. N., & Bel, E. H. (2020). Anti-alarmins in asthma: Targeting the airway epithelium with next-generation biologics. In

European Respiratory Journal (Vol. 56, Issue 5). European Respiratory Society. https://doi.org/10.1183/13993003.00260-2020

Shaheen, S. (2013). The geography of asthma and atopy: after the Berlin wall came down. *Landmark Papers in Allergy*, 226–228. https://doi.org/10.1093/MED/9780199651559.003.0069

Sinyor, B., & Perez, L. C. (2021). Pathophysiology Of Asthma. *StatPearls*.

Stern, J., Pier, J., & Litonjua, A. A. (2020). Asthma epidemiology and risk factors. In *Seminars in Immunopathology* (Vol. 42, Issue 1, pp. 5–15). Springer. https://doi.org/10.1007/s00281-020-00785-1

Types of asthma: Classification and severity. (n.d.). Retrieved March 6, 2022, from https://www.medicalnewstoday.com/articles/types-of-asthma

Wenzel, S. (2005). Severe asthma in adults. *American Journal of Respiratory and Critical Care Medicine*, *172*(2), 149–160. https://doi.org/10.1164/RCCM.200409-1181PP

Whyand, T., Hurst, J. R., Beckles, M., & Caplin, M. E. (2018). Pollution and respiratory disease: Can diet or supplements help? A review. *Respiratory Research*, *19*(1). https://doi.org/10.1186/S12931-018-0785-0

Zhang, J. M., & An, J. (2007). Cytokines, Inflammation and Pain. *International Anesthesiology Clinics*, *45*(2), 27. https://doi.org/10.1097/AIA.0B013E318034194E

Table 1: A list/summary of the biologic drugs that are presently licensed for the treating of T2-High moderate-to-severe-persistent-asthma

	Omalizumab	Mepolizumab	Relizumab	Benralizumab	Dupilumab
Mechanism of Action	Anti-IGE; inhibits the ability of IGE to attach towards its receptors situated in the mast cells and the basophils, hence preventing their activation.	Anti-ILn-5; attaches to the ILn-5 ligand and inhibits IL-5 from attaching towards the receptor	Anti-ILn-5; attaches to the ILn-5 ligand and inhibits IL-5 from attaching towards the receptor	Anti-ILn-5; attaches to the alpha subunit of the ILn-5 receptor; induces apoptosis in the both eosinophils and the basophils	Inhibits the signaling of ILn-4 and ILn-13 by binding to the IL-4 receptor-alpha
Indication	greater or equal than 6-year-old having moderate-to-severe-persistent-asthma, positive allergy tests, inadequate management with an InCS, and IGE : 30 -1300 IU/mL (for children aged 6-	≥ 12-years-old having severe-eosinophilic-asthma who were unresponsive/refractory to previous GINA Step 4-5 therapy. AEC range between 150 to 300 cells per microliter is suggested	≥12-years-old having severe-eosinophilic-asthma who were unresponsive/refractory to previous GINA Step 4-5 therapy.AEC range : greater than or equal to 400 cells per microliter is suggested	≥12-years-old having severe-eosinophilic-asthma who were unresponsive/refractory to previous GINA Step 4-5 therapy.AEC range : greater than or equal to 300 cells per microliter is suggested	≥12-years-old having severe-eosinophilic-asthma who were unresponsive/refractory to previous GINA Step 4-5 therapy.AEC range : greater than or equal to 150 cells per microliter is suggested

	11 in the United States), 30-700 IU/mL (for children aged 12 years or above in the United States), or 30-1500 IU/mL (EU)				
Dosing and Route	150-375 milligrams in the United States; 150-600 mg in the European Union	100 miligrams subcutaneously q4 weeks	3 miligrams/kg IV q4weeks is dependent on body weight.	30 miligrams SC every four weeks for 3 doses, then followed by every eight weeks after that	200 or 300 milligrams subcutaneously every two weeks
Adverse Effect	BBW: Clinical studies include a 0.1-0.2 percent risk for anaphylaxis	Hypersensitivity responses are rare, although they can occur, as can the activation of the zoster.	BBW: Clinical studies include a 0.3 percent risk for anaphylaxis	Hypersensitivity responses are quite rare with this medicine.	In rare cases, hypersensitivity responses occur; however, the incidence of the injection site reactions (which can reach upto 18 percent) and hypereosinophilia is greater (4-14 percent)

Table 2: The efficacy of biologic drugs that have been licensed by the FDA for treating of the moderate-to-severe-persistent-asthma.

	Omalizumab	**Mepolizumab**	**Reslizumab**	**Benralizumab**	**Dupilumab**
Asthma Exacerbation	25 percent reduction	Upto 50 percent reduction	Upto 50-60 percent reduction	25-60 percent reduction	50-70 percent reduction
Function Of Lung	Development is modest or ambiguous.	Inconsistent or irregular outcome	Enhanced	Enhanced	Enhanced
Corticosteroid weaning	Reduces the need of InCS, however there is no evidence that it aids with OrCS weaning.	Reduces overall OrCS usage and has been demonstrated to aid full weaning from chronic OrCS (14 percent)	Is still not been investigated particularly for such indication.	Reduces overall OrCS usage and has been demonstrated to aid full weaning from chronic OrCS (by 50%).	Reduces overall OCS usage and has been demonstrated to aid full weaning from chronic OrCS (50 percent)
Aspects Particularly Relevant	Only one SC biologic medicine has been licensed for children aged 6 to 11.	Sputum-eosinophilia still hasn't been demonstrated to be reduced by standard SC dosing. It is approved/allowed at larger doses for EGPA	The only IV biologic drug with weight-based dosage has been licensed for the asthma.	The only SC biologic drug that provides q8 week dosing	SC ,exhibited effectiveness with FreNO levels less than or equal to 25 ppb, irrespective of the eosinophil-count.

Table 3: Clinical evidence/proof of the impacts of ThSLP blocking within humans

Setting	Moderate-to-severe-asthma patients whose condition is typically uncontrolled (phase-2b-study)	Moderate-to-severe-asthma patients whose condition is typically uncontrolled (phase-2b-study)	Following an allergen challenge, patients having mild-allergic-asthma (phase-1/2a-study)	Following an allergen challenge, patients having mild-allergic-asthma (phase-1/2a-study)
End Results And Inpacts	• The exacerbation rate is decreased, regardless of the baseline blood eosinophil level/count. • Enhanced FEV1 • During the 52-week therapy timeframe, there was a reduction in blood eosinophils, FreNO and serum IGE levels.	• During the 52-week therapy timeframe, there was a reduction in blood eosinophils, FreNO, serum IGE, ILn-5, ILn-13, periostin, and also ThARC levels.	• lowered airway-hyperresponsiveness • Decreased bronchoconstriction • Eosinophils in both the blood and sputum have been lessened. • Lessened FreNO • Th2:Th1 cell ratio within blood has been decreased.	• There has been no change in the frequency of the T regulatory cells.

Figure 1: The schematic illustrating immuno-pathobiology of the asthma highlighting regions of the focused/targeted therapy with licensed and experimental mAbs.



In the asthma, airway-inflammation is caused by the imteraction/interplay of genetic predisposition and environmental factors – such as those caused by the allergens, the viruses, the pollutants, and irritants – inside the airway. If one does have high levels of T-helper cells(T2), the contact of environmental agents with the epithelium of the airway causes the production of mediators such as ILn-33, ILn-25, and ThSLP. Apart from that, allergens are collected up and delivered to naive T-helper(Th0) cells through dendritic cell antigen presentation. A sequence of steps, as depicted, occurs, which results in the synthesis of type-2 cytokines such as ILn-4, ILn-5, and ILn-13, the release of IGE by the B-cells. There are various therapeutic focuses/targets that have previously been authorized by the FDA (highlighted in red) and others that are still under research as a result of this procedure (outlined in the color green).

Figure 2: Outcomes from the EXTRA trial as well as the INNOVATE study upon the effect of omalizumab on the rate/frequency of asthma- exacerbations(A) and the (B) lung capacity/function.(McGregor et al., 2019)



Exacerbations of asthma were decreased by 25 percent in the EXTRA trial, which was examined over a 48-week period. The 95 percent confidence interval [CI] for this reduction was 8-39 percent (A). When tested over a 28-week timeframe, the INNOVATE study found that therapy using omalizumab enhanced

lung capacity/function by 94mL more than placebo, as determined by the least squares (LS)-mean change in FEV1 , compared to placebo (P =0.043). (B) *P<.05; **P<.01.(McGregor et al., 2019)

Figure 3: The SIRIUS trial that investigated overall effect/impact of the mepolizumab upon the OrCS decrease(A), (B) the frequency of the exacerbations of asthma, and (C) the control of asthma. (McGregor et al., 2019)

A B C



Throughout the SIRIUS study, the decline at the steroid dose after 24weeks reached 50 percent within group that received mepolizumab, contrasted with 0% within placebo -group (P=0.007), (A). Using mepolizumab for 24-weeks , a significant reduction was observed in the average frequency of asthma-exacerbations(P=0.04),(B). A 2-week evaluation of ACQ-5 revealed that mepolizumab was associated with an enhancement in the asthma control(P=0.004), which was persisted throughout the 24-week trial-timeframe (P=0.004) (C). (McGregor et al., 2019)

Figure 4: The BREATHE trials analyzed the performance of reslizumab on (A) the incidence of the asthma exacerbations and lung capacity/function(B) in patients. (McGregor et al., 2019)



Reslizumab was shown to lower the frequncy/rate of asthma exacerbations on two different trials, a pooled subsequent decrease was observed within asthma exacerbation frequency of 54 percent (95 percent confidence interval [CI] 42-63 percent) throughout a 52-week period in both studies (A). Furthermore, reslizumab increased lung capacity as evaluated by FEV1 by 110mL (95 percent confidence interval 67-150mL) compared to placebo, a significant difference (B) was observed. **P<.01; ***P<.001.(McGregor et al., 2019)

Figure 5: The ZONDA trial investigated the effects of benralizumab on the lowering of OrCS (A) and (B) the duration toward first exacerbation of asthma.(McGregor et al., 2019)

A

Change from Baseline oral glucocorticoid Dose



B

Time to First Asthma Exacerbation



While prescribed each four weeks or each eight weeks, benralizumab resulted in a median percentage decrease from base point in the case of steroid necessity of 75%, particularly in comparison to a 25% decrease/reduction with placebo . While administered each 4 weeks,

benralizumab was related to prolonged time towards first asthma exacerbation (hazard ratio of 0.39).(McGregor et al., 2019)

Figure 6: The VENTURE study evaluated the impact/effect of dupilumab on (A) the percentage decline at OrCS dose and on the (B) lung capacity/function. (McGregor et al., 2019)

A

Percentage Reductions Oral Glucocorticoid Dose



B

Change from Baseline in FEV1 Before Bronchodilator Use



During one very important study known as VENTURE study, the least- squares- mean percentage decrease at the OrCS dose among patients who received dupilumab during 24-weeks was - 70.1 percent (standard-error[SE] of +/- 4.9percent), compared with -41.9percent (SE of +/- 4.5 percent) within group that was treated using placebo (P<0.001)(A). The therapy with dupilumab ended up at a 220milliliters (95 percent confidence- interval 90-340 milliliter) increase in the FEV1 as versus placebo (B) after 24 weeks of treatment timeframe . The standard error is represented by the confidence intervals (CIs) bars.(McGregor et al., 2019)